Weill Cornell Medical College
Small molecular inhibitors of Rel/NF-kB
Our mission at ImmuneTarget is to develop novel Rel/NF-kB inhibitor drugs for cancer and autoimmune diseases.
ImmuneTarget, Inc. Team:
For more information about how to join us please contact Executive Director, Mary Howard at Mary@FirstXFounder.com